Genotyping to optimize antipsychotic drug treatment

Détails

ID Serval
serval:BIB_72414C8617CE
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Titre
Genotyping to optimize antipsychotic drug treatment
Titre de la conférence
International Journal of Neuropsychopharmacology
Auteur(s)
Eap Chin
ISBN
1461-1457
Statut éditorial
Publié
Date de publication
2008
Peer-reviewed
Oui
Volume
11
Série
International Journal of Neuropsychopharmacology
Pages
86
Langue
anglais
Notes
SAPHIRID:69084
Résumé
Like for other drugs, non-compliance to the pharmacological treatment is an important problem during therapy with antipsychotics. Therapeutic drug monitoring (TDM) can be useful for detecting non or poor compliance. However, while undetected plasma levels can most often be used as a proof of non-compliance (provided the use of sensitive analytical methods), low plasma levels could be due either to partial compliance and/or rapid metabolism. In vitro studies, as well as in vivo pharmacogenetic studies with phenotyping and genotyping tests, have considerably improved our knowledge on the metabolism of antipsychotics, in particular on the implications of cytochromes P450 isozymes. The pharmacokinetics of atypical antipsychotics (clozapine, olanzapine, risperidone, quetiapine, aripiprazole, sertindole and amisulpride) will be addressed, with a particular emphasis on the CYP isoforms involved in their metabolism. Examples will be given on the possible genotyping and/or phenotyping tests to be used, in addition to TDM, for determining the patients' metabolizer status (i.e slow, extensive, rapid metabolizer) and how the use of these tests could optimize antipsychotic drug treatment, and rationalize the choice of the drugs. Clinical examples will be shown of patients with demonstrated rapid metabolism of one antipsychotic, leading to poor or non-response, who had their antipsychotic doses increased to very high levels, or who had their metabolism blocked by the administration of comedications, or who were successfully switched to another antipsychotic, taking advantage of our current knowledge on the drug's metabolic and renal clearance.
Open Access
Oui
Création de la notice
18/09/2008 16:46
Dernière modification de la notice
08/05/2019 20:21
Données d'usage